Navigation Links
Corgenix Receives Additional European Patent, Announces Publication of Important Clinical Study on AtherOx(R) Technology
Date:6/22/2010

"Our study showed that patients with severe coronary artery disease (CAD) had significantly higher mean levels of Oxidized-LDL/B2-Glycoprotein I (AtherOx) complexes," said Dr. Greco, principal investigator and lead author. "This supports the concept that AtherOx is associated with severity of CAD and demonstrates a 3.5-fold-increased risk for adverse outcomes."

Corgenix, in collaboration with Dr. Greco's and other groups, are investigating additional clinical populations to further assess the utility of AtherOx in determining the level of CAD risk and the means to modify its serum levels to reduce or prevent cardiovascular adverse outcomes.

Corgenix holds exclusive worldwide licensing rights for this technology outside of Japan. The technology is incorporated in the company's AtherOx product group, a next-generation technology to identify individuals at risk for developing atherosclerotic cardiovascular disease. In all countries where the use of products employing this technology has not been cleared, the products shall not be used for diagnostic use as the performance characteristics have not been established.

About AtherOx®

The AtherOx molecule is comprised of oxidized low-density lipoprotein (oxLDL) complexed with the plasma protein B2GPI. Although oxLDL has been implicated in cardiovascular disease, according to results published in the Annals of N.Y. Academy of Science (2007), determination of oxLDL/B2GPI complexes, rather than oxLDL alone, may be a more physiologic and accurate way of assessing the risk of progressive atherosclerotic cardiovascular disease in individuals with systemic lupus erythematosus and lupus-like disorders. Corgenix licensed this technology in 2002 and is developing additional products utilizing this unique platform.


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Corgenix to Exhibit AspirinWorks(R) Test at Pri-Med New York
2. Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents
3. Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
4. Corgenix Reports Third Quarter Fiscal 2009 Financial Results
5. Corgenix to Exhibit AspirinWorks(R) Test at ACC.09
6. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
7. Corgenix to Host Conference Call to Discuss Second Quarter Results
8. Corgenix Signs Collaboration With Battelle
9. Corgenix Receives Two Additional Patents on AtherOx(R) Technology
10. Corgenix to Host Conference Call to Discuss First Quarter Results
11. Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, ... Colorado with University College Hospital (UCH) Ibadan ... development project to finance, design, construct, and operate and ... Nigeria . Under the first of the ... scoping documents and funding applications. UCH Ibadan intends to ...
(Date:7/24/2014)... processes prefer to settle into equilibriuma state of ... the realm of non-equilibrium conditions where new possibilities ... and phases, such as temperature fluctuations, freezing and ... regulate their body temperature, airplanes to fly, and ... , But even though these conditions exist naturally ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. ... developing and commercializing therapeutic products for the prevention ... announces receipt of notice on July 18, 2014 ... NYSE-MKT has accepted the CorMedix plan to regain ... As a result, the NYSE-MKT is continuing the ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... in Pharmaceutical Thin Film,Technology -, WARREN, N.J., ... specializing in quick dissolving thin film pharmaceutical products,today ... No. 7,425,292 from the,United States Patent and Trademark ... to issue on September 16, 2008, relates,to the ...
... Calif., Sept. 11 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... fourth quarter and year-end financial results on September,16, 2008., ... discuss its financial results.,Details for the fiscal year-end call ... 16, 2008 -- Time: 10:30 a.m. ET, 9:30 ...
... Deliver Yield Benefits and Value to Farmers, LONDON, ... a significant growth opportunity in continuing to create more ... and,breeding, leading to more than doubling the company,s 2007,s ... biotechnology, will,tell investors. Padgette will deliver his remarks as ...
Cached Biology Technology:MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 2MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 3Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit 2Monsanto Sees Growing Opportunity for Biotech Traits Globally 2Monsanto Sees Growing Opportunity for Biotech Traits Globally 3Monsanto Sees Growing Opportunity for Biotech Traits Globally 4
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... two factors that characterize sustainable university and college ... qualified physics teachers. Specifically, one or more faculty ... in combination with institutional motivation and commitment can ... Engineering and Math (STEM) teacher shortages are especially ... way for institutions seeking to increase the number ...
(Date:7/24/2014)... own microbial terroir, meaning the microbial populations found on ... product, creating the final flavor according to research published ... Environmental Microbiology . This is the first time investigators ... , Many sake makers inoculate with both bacteria ... the University of California, Davis, but he and his ...
Breaking Biology News(10 mins):NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2The microbes make the sake brewery 2
... studied interactions between the loggerhead turtle ( Caretta caretta ) ... water surface, mass beachings, and the effects of climate change ... marine species without causing economic losses for fishermen, the scientists ... carried out by night and in areas more than 35 ...
... EAST LANSING, Mich. A team of Michigan State ... created have uncovered the inner workings of a ... develop new medicines or understand how enzymes repair DNA. ... bacterial enzyme that is important in metabolism. Enzymes in ...
... Copenhagen summit to draft a legally binding agreement on the ... that we will see further rapid changes in the global ... the planet,s most vulnerable species at this time of unprecedented ... on 26 February 2010 in the Journal of Experimental ...
Cached Biology News:How can accidental captures of loggerhead turtles be reduced? 2MSU scientists unlock key enzyme using newly created 'cool' method 2Tackling the challenges of survival in a changing world 2Tackling the challenges of survival in a changing world 3